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Abstract: Nucleic Acid Programmable Protein Arrays (NAPPA) have emerged as a 
powerful and innovative technology for the screening of biomarkers and the study of  
protein-protein interactions, among others possible applications. The principal advantages 
are the high specificity and sensitivity that this platform offers. Moreover, compared to 
conventional protein microarrays, NAPPA technology avoids the necessity of protein 
purification, which is expensive and time-consuming, by substituting expression in situ 
with an in vitro transcription/translation kit. In summary, NAPPA arrays have been broadly 
employed in different studies improving knowledge about diseases and responses to 
treatments. Here, we review the principal advances and applications performed using this 
platform during the last years. 
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1. Introduction 
The complexity of the human proteome requires high-throughput (HT) approaches to define its 
study. During the last decade, protein microarrays have emerged as a useful tool for the analysis of the 
proteome at large scale [1]. Currently, protein microarrays have been successfully applied in the study 
of biomarkers, post-translational modifications (PTMs) of proteins, and various types of interactions 
with proteins. In addition, they have shed light on the biological roles of proteins related to and 
involved in diseases [2–4]. 
Although recent advances have improved the sensitivity and reproducibility of common and 
widespread proteomics technologies (such as 2D-GE, MALDI-TOF, or LC-MS/MS), they are not 
readily implemented in a HT format [5]. In contrast with other proteomic strategies, protein 
microarrays avoid the need for pre-fractionation of the sample. In fact, complex and non-fractionated 
proteome mixtures, such as serum, plasma, urine and tissue extracts, can be directly used for 
experimentation [2]. For this reason, protein microarrays offer a powerful technology for functional 
proteomics analysis in HT format. 
Microarray technologies utilize densely printed micro- or nano-spots of capture ligands 
immobilized onto a solid support that are exposed to samples containing the corresponding binding 
molecules (often referred to as queries), allowing the simultaneous analysis of thousands of capture 
targets within the same assay [6,7]. Thus, protein array technology enables multiplex and highly 
sensitive protein assays capable of handling and resolving complex proteomes with limited available 
samples [5,7]. 
In general, protein microarrays can be prepared in different formats (planar, beads…) and wide 
diversity of content (from antibodies and recombinant proteins to cell lysates). In fact, researchers have 
classified protein arrays based on the format or the content; however, in practice, these differences are 
more related to nomenclature than methods. 
The first critical step to build protein microarrays is to display proteins on a solid surface for the 
detection of their biochemical activities in a multiplex manner. Hence, this is considered one of the 
challenges in protein microarrays field because of the high variability in biochemical properties (such 
as oligomerization states, PTMs, stability, affinities and specificities, isoelectric point…). 
In addition, protein production and purification in a HT manner with high yield can be  
challenging [8]. This is because cell-based expression systems and the protocols of purification to 
generate large quantities of proteins are usually very tedious, result in highly variable yields and do not 
guarantee the protein integrity. These issues represent one of the major bottlenecks in HT functional 
proteomics studies. In Nucleic Acids Programmable Protein Arrays (NAPPA), the proteins are 
synthetized from a DNA template directly onto the surface of the array and the nascent protein is 
captured at the same time by an affinity reagent [9] avoiding the vast majority of drawbacks mentioned 
above (Figure 1). 
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Figure 1. Diagram of Nucleic Acid Programmable Protein Array (NAPPA). Bovine serum 
albumin is used for printing purified template DNA (including the protein of interest and  
a tag molecule) onto a slide together with an antibody that recognizes the specific tag. 
When the cell extract is added, the transcription and translation are initiated and the 
expressed protein is captured by the anti-tag antibody. 
Here, we briefly review NAPPA technology and its recent applications in the study of pathologies, 
discovery of biomarkers and also vaccine development. 
2. Concept of Protein Microarrays 
In 2004, LaBaer’s lab designed and developed a novel protein microarray, termed NAPPA, based 
on shuttling cDNA clones into expression plasmids—typically using Gateway technology—adding a 
transcriptional promoter and also an in-frame polypeptide capture tag. 
Cloning the cDNAs into a specialized vector requires a much greater upfront investment compared 
to the conventional Polymerase Chain Reaction (PCR). However, there are several advantages over 
typical protein microarrays that establish NAPPA technology as a powerful platform: (i) the 
production of a glycerol stock for the clone allows the maintenance of the gene integrity indefinitely; 
(ii) it ensures high fidelity since the clone sequence is verified; and (iii) inserting the clones into 
plasmids permits the incorporation of tags and antibiotic resistance genes for specific selection. 
Generally, proteins are fused with glutathione-S-transferase (GST) in NAPPA technology; however, 
other tags such as flag, hemagglutinin (HA), c-Myc, and Halo tags have been used for specific applications. 
Bacteria cultures are employed as hosts for the high quality supercoiled plasmid DNA of interest. 
Thus, after the purification of the DNA plasmids, these are printed onto an activated ester surface 
along with a homo-bifunctional crosslinker (BS3, SMCC…), bovine serum albumin (BSA) and anti-tag 
antibody. BSA efficiently increases the DNA binding and reduces the unspecific interactions, whereas 
the anti-tag antibody attaches the expressed protein [10]. When the cell-free expression system is 
added to the array, a coupled transcription/translation reaction results and the nascent protein is linked 
to the capture agent tag through the C-terminal end assuring the complete translation of the protein 
(Figure 2). A cell-free expression system produces a protein by using biomolecular translation 
machinery without the usage of living cells. The reaction solution includes the transcriptional and 
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translational molecular machinery consisting of RNA polymerases for mRNA transcription, ribosomes 
for polypeptide translation, tRNA and amino acids, enzymatic cofactors, an energy source, and cellular 
components essential for proper protein folding. 
 
Figure 2. Scanning images showing the spots corresponding to DNA printed onto the 
surface before the protein expression (A) and the spots for the expressed proteins after the 
incubation with the anti-tag antibody (B). 
In an updated version of NAPPA, LaBaer and colleagues built an array of 1000 human genes and 
demonstrated that the vast majority of these genes (~96%) showed a detectable protein signal. In 
addition, they concluded that this platform is unbiased in relation to protein size—signal intensities 
were independent from molecular size—enabling unbiased study of protein function in a HT manner. 
In turn, they demonstrated their high stability since the DNA is more stable than proteins. Moreover, 
there is high intra- and inter-protein display reproducibility in these kinds of arrays [9]. It is also 
remarkable that NAPPA is the only in situ protein technology that has been widely employed in 
biological and biomedical research studies. To date, more than 30,000 different proteins have been 
produced on NAPPA arrays, including whole proteomes of several microorganisms and >12,000 
different full-length human proteins. All in all, thousands of NAPPAs can be produced per year thanks 
to the automation developed in the field. 
3. Applications of NAPPA Technology 
Next, different applications of NAPPA technology are described showing several studies and their 
results. These applications are classified according to protein-protein interactions studies, vaccine 
development and the evaluation of autoimmune responses (Figure 3). Table 1 summarizes the main 
studies developed in the field and described in the text. 
A. cDNA Staining B. Protein Display
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Figure 3. Applications of NAPPA technology. 
3.1. NAPPA Technology for Understanding Proteins-Proteins Interactions 
Four years after the first design of NAPPA technology, LaBaer’s group confirmed that protein 
function is maintained in printed proteins on high-density arrays. With this purpose, they designed an 
array expressing 647 unique genes in duplicate and tested for several well-characterized interactions, 
Jun-Fos and p53-MDM2 among others. Simultaneously, they expressed the corresponding protein 
printed on the array and co-expressed the query protein by adding the appropriate cDNA to the cell-free 
expression lysate. Using specific antibodies against Jun, Fos and MDM2, they detected specific 
interactions of these proteins. It is also necessary to take into account that protein function can be 
compromised by lack of PTMs and/or misfolding of certain domains due to the absence of chaperones 
and cofactors. Concerning the lack of PTMs, it is possible to use alternative cell free expression 
systems depending on the protein to be expressed. Thus, different expression systems have been 
developed (including HeLa, Leishmania, E. coli, rabbit expression systems, among others). Also, 
including ribosomal machinery and chaperones (such as HSP90 or HSC70) may encourage the folding 
of large multi-domain proteins [9]. 
More recently, in 2012, Fuentes and collaborators published a work in which a total of 450 mRNAs 
from O. moubata tick salivary glands were extracted and purified, and then transfected into a donor 
vector (pDONR222) generating a library of cDNA. Finally, this library was transfected again into a 
library destination expression vector (pANT7_GST), which allows in situ expression of GST-tagged 
proteins in cell-free systems. They built a NAPPA array randomly choosing 480 clones with validated 
sequences. After confirming successful display of the recombinant fused GST tag protein, the correct 
display of individual tick proteins was also checked with serum recognizing Om44, a P-selectin 
salivary protein from O. moubata whose neutralization induces antibody block tick feeding. To test the 
functionality of the proteins in the array, they performed protein-protein interaction studies with the 
recombinant P-selectin/Fc chimera. With this aim, the proteins on the array and P-selectin/Fc chimera 
were expressed in situ normally and also in the presence of canine pancreatic microsome membranes 
(CMMs). They found that P-selectin/Fc chimera interacted with phospholipase A2 (PLA2) expressed  
in situ on the array. This finding suggested that this secreted O. moubata PLA2 (sPLA2) could be a 
potential P-selectin interacting partner [11]. 
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As another example, a NAPPA array was designed for systematic characterization of viral  
protein-host interactions. Through the access to viral ORFs in flexible cloning formats, the LaBaer’s 
lab is releasing the initiation of a panviral proteome collection of 2035 ORF clones from 830 viral 
genes in the Gateway® recombinational cloning system. In this work, NAPPA arrays are suitable, 
highly efficient and flexible platforms for displaying viral proteins and detecting host serological 
responses using micro-fluidic multiplexed immunoassays and allowing the study of host-viral protein 
interactions [12]. Related to host-pathogen interactions in Legionella pneumophila infections, this 
group have applied NAPPA technology to determine the interaction network of the pathogen with 10,000 
unique human proteins. They identified known and novel interaction candidates and, additionally, 
substrates for an effector with and adenylyl transferase domain that catalyzes AMPylation. Their results 
highlighted the amenability of NAPPA to high-throughput analysis of effectors from a wide variety of 
human pathogens [13]. 
Nicolini and collaborators clinically screened neuro-oncological patients respondent to 
temozolomide (TMZ) from those showing resistance to the drug by using a NAPPA-based 
nanoconductometric sensor [14]. Their results shower a properly discrimination of protein-protein 
interactions depending on the behavior against TMZ [15]. Finally, Liang et al. have successfully 
coupled two different technologies (label-free and real-time detection method plasmonic-based 
electrochemical impedance microscopy with NAPPA arrays) to determine small molecule binding 
kinetics. This approach allowed the measurement of binding kinetics and affinity parameters between 
small molecule drugs (imatinib and SB201290) and their target proteins (kinases ABl1 and p38-α) 
with high sensitivity and reproducibility. These results demonstrate that NAPPA methodology is a 
reliable technology to understand small molecules interactions in biological systems and is also useful 
in the discovery of small molecules drugs [4]. 
3.2. Vaccine Development by NAPPA Technology 
Since the development of NAPPA arrays, many research groups have used different  
NAPPA-based platforms for investigating immune diseases and improving vaccine development. 
Next, we briefly describe some of these studies. 
Respiratory tract and lung infections in cystic fibrosis (CF) patients and individuals who are 
otherwise immune compromised can be caused by a gram-negative bacterium called Pseudomonas 
aeruginosa. This microorganism was selected by Montor et al. [16] to test candidate membrane 
antigens with NAPPA arrays. The principal goal of their work was to map the immune responses of 
patients infected with P. aeruginosa to determine which bacterial outer membrane proteins induced a 
strong immune response. The principal difficulty in purifying membrane proteins to display on 
NAPPA arrays is related to their hydrophobic domains. They designed a NAPPA array containing all 
262 outer membrane proteins of the bacterium. Serum samples from 22 CF patients with documented 
pseudomonal pneumonia and 16 non-CF individuals with various acute P. aeruginosa infections as well 
as 15 healthy controls were selected for array screening. After analysis, 12 proteins triggering an 
adaptive immune response were identified in a majority of the infected patients, yielding valuable 
information about which bacterial proteins are recognized by the immune system during the natural 
course of infection. 
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In turn, Ceroni and colleagues [17] used NAPPA arrays for a systematic analysis of the IgG antibody 
immune response against varicella zoster virus (VZV), a human herpes virus, encoding at least 69 
distinct viral proteins, which causes chickenpox after primary infection and shingles during reactivation. 
Its effects are particularly important in pregnancy and immunocompromised patients and sera-diagnostic 
tests are commonly used for its detection. In order to investigate the humoral immune response to VZV 
infection or vaccination in more detail, Ceroni developed a specific NAPPA array containing all 69 VZV 
proteins mentioned above and performed a detailed analysis of 68 sera from individuals with either no 
infection or an acute VZV infection. The obtained results confirmed previous knowledge about viral 
open reading frames (ORF) such as reactive glycoproteins antigens (ORF 5, ORF 14, ORF 31, ORF 37, 
ORF 68), and also found novel responses against a variety of other membrane proteins (ORF2, ORF24), 
capsid (ORF20, ORF23, ORF43) and tegument (ORF53, ORF9, ORF11), as well as others related to 
virus replication (i.e., ORF 25, ORF26, ORF28) and transactivator proteins (ORF12, ORF62 and ORF63). 
3.3. Evaluation of Autoimmune Responses 
In autoimmune diseases, antibodies, known as “auto-antibodies,” are often generated by the humoral 
immune system against self-proteins in response to many pathological processes. This kind of antibody 
follows a specific pathway to recognition by the immune system, including antigen over-expression, 
mutation, and/or altered PTM released from damaged tissues [18,19]. The presence of these 
autoantibodies is related to the development of certain diseases such as diabetes. Thus, they can be 
useful as diagnostic/prognostic biomarkers [20]. As diagnostics they have several key advantages: 
(i) they can be detected even before the appearance of clinical symptoms; (ii) even if the antigen that 
induced them is absent or present at very low amounts, the antibodies can be readily detected;  
(iii) they can be measured from easily obtained sources such as blood other body fluids; (iv) they are 
very stable in standardized collection vessels; and (v) they are straightforward to measure using many 
available chemistries. 
In 2007 Anderson and colleagues employed NAPPA arrays for serological screening in breast 
cancer. After NAPPA design, they tested p53 together with other three negative control antigens 
(S100A7, p21 and ML-IAP) with positive and negative p53 sera confirming the expression for all the 
proteins printed and checking the detection of antibodies against p53. Moreover, they determined 
differences in p53-expression levels between healthy donors and breast cancer patients, and also within 
disease stages. In addition, they confirmed that many regions of the protein expressed were accessible 
on the arrays. To extend the study to autoantibody biomarker detection, they built a high density 
NAPPA array printing 1117 cancer related genes of which 539 were implicated on breast cancer and 
tested them against melanoma, ovarian and breast cancer sera [21]. Later, they increased the number of 
novel autoantibodies to be tested in breast cancer (around 4988 candidate antigens). Finally they 
identify 28 autoantibodies that could distinguish between benign breast disease and invasive cancer in 
a blinded study [22]. 
Recently, LaBaer et al. developed several NAPPA studies for juvenile idiopathic arthritis (JIA) [23] 
and type 1 diabetes (T1D). In both cases, serological autoantibodies (AAbs) from the disease were 
screened using a two-stage method. Firstly, more than 6000 unique proteins were displayed in NAPPA 
arrays which were incubated with 50 sera from T1D patients and 20 from controls allowed the 
elimination of uninformative antigens. In the second stage, 750 remaining genes were printed in 
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duplicate and 26 proteins were identified as novel AAbs (TBCA, CDK4, CDK6, TBRG4, among 
others) with p < 0.005 [24]. For juvenile idiopathic arthritis, they assessed the levels of antibodies 
present in the systemic circulation and synovial joint of a small cohort of juvenile arthritis patients as a 
pilot study. Their results showed a strong correlation between the circulating antibody levels and those 
of the inflamed joint. 
In 2009, Wong et al. adapted NAPPA technology to the Luminex suspension bead array platform to 
monitor the humoral immunity. To accomplish this, they expressed the proteins and captured them 
with the Luminex beads through anti-tag antibodies. After mixing the antigen-loaded beads, serum was 
added and human IgG was detected with standard secondary detection reagents. Protein arrays are a 
useful method for testing a moderate number of clinical samples against thousands of candidate 
proteins. The advantage of the Luminex approach is that it allows testing hundreds of clinical samples 
against a moderate number of candidate antigens, i.e., mesoscale. They concluded that detection of 
antibodies was highly reproducible and the specificity and limits of detection of the platform were 
comparable to standard ELISAs [25]. 
Recently, Henjes and Lourido have performed an analysis of auto-antibody profiles in osteoarthritis 
(OA) using comprehensive protein arrays concepts. In this work, NAPPA arrays and antigen arrays 
have been used to characterize differential autoantibody profiles in a set of 62 samples from OA, 
rheumatoid arthritis (RA), and healthy controls. An untargeted screen was performed on 3840 protein 
fragments spotted on planar antigen arrays, and 373 antigens were selected for validation on 
bead-based arrays. In the NAPPA approach, a targeted screening was performed on 80 preselected 
proteins. The autoantibody targeting CHST14 was validated by conventional ELISA assays in the 
same set of patients. Altogether, nine and seven disease-related autoantibody target candidates were 
identified, respectively, and this work demonstrated a combination of these two array concepts for 
biomarker discovery and their usefulness for characterizing disease-specific autoantibody profiles [26]. 
4. Recent Technical Advances to the Platform 
Several developments in protein array technology have allowed an improvement in throughput and 
sensitivity, achieving better capture and probing of proteins. 
For instance, Wang and colleagues have described the use of human cell-free lysates (HeLa cell 
lysate as an in vitro transcription/translation system) in NAPPA arrays for protein expression 
enhancing protein yield and for presenting both natural and denatured forms of proteins for antibody 
biomarker discovery. Through their results, they demonstrated that autoantibody profiles from 
denatured protein arrays were distinct from those native protein arrays when probing with plasma 
samples. Furthermore, they blocked the protein arrays with E. coli lysates, reducing the background 
and improving the antibody signals [27]. Another study from the same lab reported an improvement in 
protein display by using the human cell-free lysate (10-fold higher) compared to the conventional 
rabbit reticulocyte lysate [28]. In turn, Xiabo and collaborators used NAPPA technology for the 
detection of global pathogen-host AMPylation (adenylytation PTM). Specifically, they developed a 
novel nonradioactive AMPylation screening platform using high-density cell-free protein microarrays 
for the screening of 10,000 unique human proteins with Vibrio parahaemolyticus and Histophilus 
somni, identifying new AMPylation substrates (including Rac 2 and Rac 3) [29]. 
Microarrays 2015, 4 222 
 
Collaboration between the Nicolini and LaBaer groups reported an innovative kind of NAPPA 
platform, in which the cDNA includes the SNAP tag and the expression is performed by using the 
PURE system (reconstituted from the purified components necessary for E. coli translation). Their 
principal purpose was to achieve the combination of mass spectrometry and fluorescence technology 
for protein microarrays. Their results with the PURE system showed a protein yield about 20 times 
higher with respect to the rabbit reticulocyte expression system [30]. 
Additionally, LaBaer’s lab has developed a very high density NAPPA array without any diffusion or 
contamination between spots by depositing the samples on 8000 nano-volume wells and, recently, 
the protein expression lysate into each well to achieve the protein expression in a HT manner. 
Furthermore, they present preliminary results with an ultra-high density protein array including up to 
24,000 nanowells [31]. 
In turn, Nicolini and collaborators demonstrated the effective use of label-free approaches (anodic 
porous alumina, APA; and atomic force microscopy, AFM) in combination with NAPPA technology 
to test the expression and the atomic structure of proteins of interest. These studies show the possibility 
of overcoming limitations at the fluorescence detection level [32]. 
Table 1. Summary of NAPPA protein microarray applications. 
Description Aim/Results Reference 
High density array (1000 human genes/array) 
96% detectable signal 
Unbiased to protein size 
No difference or contamination between spots 
[9,31] 
450 mRNA O. moubata tick salivary glands 
P-selectin/Fc chimera interaction with 
phospholipase A2 
[11] 
Systematic characterization of viral protein-host 
interactions 
Panviral Proteome Collection [12] 
Neuro-oncological patients respondent to TMZ Discrimination of protein-protein interactions [14,15] 
Label-free techniques coupled to NAPPA Determination of small molecule binding proteins [4] 
Respiratory tract and lung infections in cystic 
fibrosis 
To test candidate membrane antigens  [16] 
Analysis of IgG antibody immune response against 
VZV 
To identify known and novel antigens [17] 
Serological screening in breast cancer 
Protein profiling to distinguish benign breast 
disease and invasive cancer 
[21] 
Juvenile idiopathic disease and type 1 diabetes 
To screen for disease-specific autoantibodies in 
plasma samples. 
[23] 
NAPPA coupled to Luminex suspension bead array 
platform 
To monitor the humoral immunity [25] 
Osteoarthritis and rheumatoid arthritis To characterize differential autoantibody profiles [26] 
Use of HeLa cell-free lysates To enhance protein yield [27] 
A nonradioactive AMPylation screening platform 
using high-density cell-free protein microarrays 
To identify novel substrates of AMPylators with 
different domains or in different species 
[29] 
SNAP tag 
Combination of MS/MS and fluorescence 
technology 
[30] 
APA and AFM coupled to NAPPA 
To test the expression and atomic structure of 
proteins 
[32] 
TMZ, temozolomide; NAPPA, Nucleic Acid Programmable Protein Array; VZV, varicella zoster virus; APA, 
anodic porous alumina; AFM, atomic force microscopy.  
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5. NAPPA Alternative Methods 
Besides NAPPA technology, several in situ expressed microarrays have been developed, such as 
protein in situ arrays (PISA) and printing protein arrays from DNA (DAPA). The main difference 
between PISA and NAPPA is that the DNA template is added as a free molecule together with the 
reaction mixture. Thus, it is not necessary to immobilize the DNA onto the surface [33]. Angenendt and 
colleagues demonstrated that yield signals for protein expressed with these arrays were comparable to 
300 μg/mL directly spotted proteins. Moreover, the volume of required sample was too low 
(subnanotliter volumes) and the nature of the surfaces determined the protein binding. Thus, the nickel 
chelate-coated slides generated an unspecific binding. Finally, they refined and miniaturized PISA arrays 
by using multiple spotting technique to get a high-density protein microarray with up to 13,000 spots [34]. 
On the other hand, the DAPA strategy, developed in 2007, is characterized by assembly  
face-to-face between a slide containing the DNA templates for the proteins and a second slide 
pre-coated with a protein-capturing reagent. For the transcription/translation, the cell-free system is 
placed between the two slides using a cell-extract soaked membrane [35,36]. Although this is the basis 
of the technology, modifications can be made to improve its functionality. In such a way, Schmidt and 
colleagues [37] have investigated the influence of different support coatings (Ni-NTA, Epoxy, 
3D-Epoxy and Polyethylene glycol methacrylate (PEGMA)) concluding that their optimal combination 
results in high protein yields and optimized spot morphology. Moreover, using a tag-specific capture 
antibody on a protein repellent surface coating, they improved the specificity of protein capturing and 
obtained amounts of expressed proteins comparable to classical protein arrays. 
Finally, ProtoArrays are also a remarkable microarray approach. They are characterized for 
including thousands of proteins (>9000) in a high-density array allowing a high-throughput screening 
using low volumes of sample (~10 μL of serum). Several studies have been performed by using these 
arrays. For instance, they are employed for autoimmune antibody screening studies to discover 
biomarkers of the Parkinson’s disease (ParkCHIP). In this research, Turewicz and collaborators [38] 
studied a large cohort of samples and adapted the default workflow for these arrays to their 
requirements. This constitutes a clear example of the flexibility of this approach. Furthermore, these 
ProtoArrays have been employed to study systemic erythematosus lupus (SLE), specifically to identify 
novel autoantibodies associated with the disease. In total, 9500 antigens were screened resulting in 446 
IgG and 1218 IgM autoantibodies significantly elevated in SLE patients. In this research, the 
researchers not only identified previously described autoantibodies (SSA/SSB, Sm/RNP…) but also 
reported novel antigens associated with the nucleus, cytoplasma or membrane [39]. 
6. Conclusions and Future Perspectives 
The development of new strategies for protein profiling may improve analysis and reduce the time 
for screening of thousands of proteins simultaneously. In addition, the expression of the proteins at the 
moment of usage improves the quality of the proteins, since the final product does not suffer any 
change related to temperature, pH or degradation. The use of mammalian ribosomes and chaperone 
proteins contributes to accurate protein folding. Unlike conventional protein arrays, nucleic acid 
programmable protein arrays (NAPPA) are DNA-based arrays that convert into protein microarrays. A 
key advantage of this approach is its adaptability. To display a different set of proteins—the proteins 
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of a recently discovered pathogen, a set of proteins related to a gene family, or a series of mutant 
versions of a protein of interest—the practitioner merely has to produce the DNA clones encoding  
the proteins. There is no need to go through a long development process of purifying the proteins.  
To produce the protein of interest, the coding-DNA inserted into a plasmid is printed onto a surface 
and then is transcribed/translated by using a cell-free expression system. Moreover, once printed, the 
coding material remains intact, even at ambient temperature, thanks to the high stability of nucleic 
acids. The labile protein is not expressed until it is required. 
Many investigators have employed this NAPPA approach for their studies, including cancer, 
autoimmune diseases, host-pathogens interactions, quantification of protein binding kinetics, and 
infection responses to microorganisms showing a high specificity and selectivity with accurate and 
reproducible results. Moreover, it has been demonstrated that the platform is unbiased and independent 
of molecular size or protein family type. 
In summary, NAPPA technology seems to be a powerful tool for performing HT analysis in 
different formats (planar, beads…), with different samples (sera, urine, saliva…) and combined with 
other platforms. All in all, clinical and diagnostic screenings may be accomplished in a rapid and 
reliable manner. 
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